Autoantibody as markers of the heart state in patients with vibration disease burdened diabetes mellitus

Physical and chemical factors, obesity, lipid metabolism disorder, diabetes affect the state of the vascular endothelium, the processes of thrombus formation, fibrinolysis and increase the risk of developing cardiovascular diseases. It can be assumed that the development and course of pathological processes in the cardiovascular system, caused by vibration disease with the onset of diabetes, will undergo changes. The purpose of the study was to assess the state of heart condition according to the level of specific autoantibodies with the combined effect of vibration disease and type 2 diabetes mellitus. Patients with vibration disease (group I), patients with type 2 diabetes (group II) and persons with vibration disease in combination with type 2 diabetes (group III) were examined. Individuals do not have a history of coronary heart disease, stroke, and myocardial infarction have been included in obsledrovanie. Serum levels of specific autoantibodies characterizing the state of the heart have been studied. It was revealed that the content of autoantibodies to 1-adrenoreceptors in patients of group I was higher than in individuals of group II. The relative content of autoantibodies to the components of the membrane and cytoplasm of myocardial cells in patients of groups I-III did not differ. It was found that elevated levels of autoantibodies to components of the membrane and cytoplasm of myocardial cells, cardiomyosin, 1-adrenoreceptors were observed more often in patients with vibration disease combined with diabetes and in persons with vibration disease than in people with diabetes. Persons with a reduced content of autoantibodies to 1-adrenergic receptors were not detected among patients of groups I and III. Changes in the levels of specific autoantibodies in persons with vibration disease may indicate the development of functional metabolic and structural changes in the heart, disorders of its electrical activity that have not yet been manifested in the form of a pathological process. Lower levels of 1-adrenoceptor autoantibodies in patients with type 2 diabetes without vibration disease can be caused by increased levels of catecholamines, which is characteristic of diabetics. Further research, including clinical data and indicators of functional diagnostics is necessary to confirm our assumptions.

1. Bodienkova G.M., Kurchevenko S.I. Assessment of inflammation mediators under exposure to the vibration in employees in dependence on pronouncement of the pathological process. Gigiena i sanitariya = Hygiene and Sanitation, 2017, Vol. 96, no. 5, pp. 460-462. (In Russ.)

2. Bodienkova G.M., Kurchevenko S.I. Influence of industrial vibration on the level of antibodies against regulatory proteins of the nervous tissue. Fiziologiya cheloveka = Human Physiology, 2016, Vol. 42, no. 5, pp. 97-101. (In Russ.)

3. Gupalo E.M., Mironova N.A., Malkina T.A., Polevaya T.Yu., Golitsyn S.P. The role of inflammation in heart rhythm and conduction disturbances. Sibirskiy meditsinskiy zhurnal = Siberian Medical Journal, 2015, Vol. 30, no. 1, pp. 16-21. (In Russ.)

4. Kologrivova I.V., Suslova T.E., Vinnitskaya I.V., Koshelskaya O.A., Boshchenko A.A., Trubacheva O.A. Immunoregulatory imbalance and functional state of the heart in the patients with diabetes mellitus type 2. Meditsinskaya immunologiya = Medical Immunology (Russia), 2018, Vol. 20, no. 6, pp. 833-846. (In Russ.) doi: 10.15789/1563-0625-2018-6-833-846.

5. Kostyukevich M.V., Zykov K.A., Mironova N.A., Agapova O.Yu., Shevelev A.Ya., Efremov E.E., Vlasik T.N., Golitsyn S.P. Role of autoantibodies against pi-adrenergic receptor in cardiovascular disease. Kardiologiya = Cardiology, 2016, no. 12, pp. 82-91. (In Russ.)

6. Moiseeva O.M., Mitrofanova L.B., Nakatseva E.V., Zverev D.A., Skurydin S.V., Poletaev A.B. Comparative analysis of the serum level of autoantibodies as a diagnostic tool of myocardial inflammatory diseases. Terapevticheskiy arkhiv = Therapeutic Archive, 2012, Vol. 84, no. 9, pp. 47-52. (In Russ.)

7. Naumova O.V., Kudaeva I.V., Masnavieva L.B., Dyakovich O.A., Belik V.P. Molecular genetic aspects of endothelial dysfunction in individuals exposed to mercury. Meditsina truda i promyshlennaya ekologiya = Occupational Health and Industrial Ecology, 2017, no. 1, pp. 10-13. (In Russ.)

8. Poletaev A.B. Physiological immunology - natural autoantibodies and problems of nanomedicine. Moscow: Miklosh, 2011. 220 p.

9. Poryadin G.V., Oskolok L.N. Pathophysiology of metabolic syndrome. Lechebnoe delo = Medicine, 2011, no. 4, pp. 1-10. (In Russ.)

10. Rogova M.M., Mironova N.A., Rodionova E.S., Malkina T.A., Zykov K.A., Bespalova Zh.D., Bibilashvili R.Sh., Efremov E.E., Golitsyn S.P. Titers of antibodies to 31-adrenoceptor and M2 cholinergic receptors in patients with ventricular arrhythmias without an organic cardiovascular disease and their possible clinical significance. Ratsionalnaya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology, 2012, Vol. 8, no. 5, pp. 647-654. (In Russ.)

11. Spiridonova N.V., Basina E.I, Shchukin V.Yu. Natural (physiological) autoantibodies and regulation of homeostasis. Izvestiya Samarskogo nauchnogo tsentra RAN = News of Samara Scientific Center of the Russian Academy of Sciences, 2015, Vol. 17, no. 5-3, pp. 861-867. (In Russ.)

12. Shpagina L.A., Gerasimenko O.N., Drobyshev V.A., Kuznetsova G.V. Endothelial hemostatic predictors of cardiovascular risk in patients with vibration disease in combination with the arterial hypertension. Sibirskiy meditsinskiy vestnik = Siberian Medical Bulletin, 2017, no. 1, pp. 5-8. (In Russ.)

13. Shpagina L.A., Tretyakov S.V., Voitovich T.V. Function of circulation system in the course of arterial hypertension treatment in patients with vibration disease. Terapevticheskiy arkhiv = Therapeutic Archive, 2003, Vol. 75, no. 2, pp. 58-61. (In Russ.)

14. Yamshchikova A.V., Fleishman A.N., Gidayatova M.O., Neretin A.A., Kungurova A.A. Features of vegetative regulation in vibration disease patients, studied on basis of active orthostatic test. Meditsina truda i promyshlennaya ekologiya = Occupational Medicine and Industrial Ecology, 2018, no. 6, pp. 11-14. (In Russ.)

15. Caforio A.L.P., Tona F., Bottaro S., Vinci A., Dequal G., Daliento L., Thiene G., Iliceto S. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity, 2008, Vol. 41, no. 1,pp. 35-45.

16. Chiale P.A., Garro H.A., Schmidberg J., Sanchez R.A., Acunzo R.S., Lago M., Levy G., Levin M. Inappropriate sinus tachycardia may be related to an immunologic disorder involving cardiac beta andrenergic receptors. Heart Rhythm, 2006, Vol. 3, no. 10, pp. 1182-1186.

17. Du Y., Yan L., Wang J., Zhan W., Song K., Han X., Li X., Cao J., Liu H. p1-adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the p1-AR/cAMP/PKA and p38 MAPK pathways. PLoS ONE, 2012, Vol. 7, no. 12, 52911. doi: 10.1371/journal.pone.0052911.

18. Hirata M., Sakakibara H. Visually-evoked P300 and NOGO potentials as indicators of central nervous system function in patients with vibration syndrome. Int. Arch. Occup. Environ. Health, 2008, Vol. 82, no. 1, pp. 79-85.

19. Ippoliti F., Canitano N., Businaro R. Stress and obesity as risk factors in cardiovascular diseases: a neuroimmune perspective. J. Neuroimmune Pharmacol., 2013, Vol. 8, no. 1, pp. 212-226.

20. Iwata M., Yoshikawa T., Baba A., Anzai T., Mitamura H., Ogawa S. Autoantibodies against the second extracellular loop of the beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol., 2001, Vol. 37, pp. 418-424.

21. Liu H.R., Zhao R.R., Zhi J.M., Wu B.W., Fu M.L. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity, 1999, Vol. 29, no. 1, pp. 43-51.

22. Milicevic G., Udiljak N., Milicevic T. Changes in vagal reactivity to the sympathicotonia during the progression of heart failure: from self-suppression to counteraction. Med. Hypotheses, 2013, Vol. 81, no. 2,pp. 264-267.

23. Poletaev A.B., Churilov L.P., Stroev Y.I., Agapov M.M. Immunophysiology versus immunopathology: natural autoimmunity in human health and disease. Pathophysiology, 2012, Vol. 19, no. 3, pp. 221-231.

24. Stavrakis S., Kem D.C., Patterson E., Lozano P., Huang S., Szabo B., Cunningham M.W., Lazzara R., Yu X. Opposing cardiac effects of autoantibody activation of beta-adrenergic and M2 muscarinic receptors in cardiac-related diseases. Int. J. Cardiol., 2011, Vol. 148, no. 3, pp. 331-336.

25. Steinberg S.F. Beta1-adrenergic receptor regulation revisited. Circ Res., 2018, Vol. 123, no. 11, pp. 1199-1201.

26. Wulsin L.R., Horn P.S., Perry J.L., Massaro J.M., d’Agostino R.B. Autonomic imbalance as a predictor of metabolic risks, cardiovascular disease, diabetes, and mortality. J. Clin. Endocrinol. Metab., 2015, Vol. 100, no. 6, pp. 2443-2448.